Monocyte-derived dendritic cells from HLA-matched allogeneic donors showed a greater ability to induce leukemic cell-specific T cells in comparison to leukemic cell-derived dendritic cells or monocyte-derived dendritic cells from AML patients.
We investigated the usefulness of allogeneic monocyte-derived dendritic cells (allogeneic mDCs) pulsed with leukemic lysates in acute myeloid leukemia (AML). Allogeneic mDCs showed higher expressions of several molecules (HLA-DR, CD80, CD83 or CD86), higher production of IL-12 and higher capacity to stimulate allogeneic T cells compared to both leukemic DCs and autologous mDCs. Autologous T cells primed by allogeneic mDCs displayed a larger number of interferon-gamma-secreting cells against leukemic cells than those primed by either leukemic DCs or autologous mDCs. These results suggest that monocyte-derived DCs from HLA-matched allogeneic donors can be used as an alternative to generate leukemia-specific cytotoxic T cells and to overcome the limitation of leukemic DCs or autologous mDCs.